BOCA RATON, Fla., Nov. 29, 2018 /PRNewswire/ -- Sensus
Healthcare, Inc. (NASDAQ: SRTS), a medical device
company specializing in the non-invasive treatment of non-melanoma
skin cancers (NMSC) and keloids with Image-Guided Superficial
Radiation Therapy (IGSRT), has installed its first SRT-100+ system
at Hillcrest Plastic Surgery in Orlando,
Fla., specifically for the treatment of keloid scars.
Earlier this year, Sensus received 510(k) clearance from the U.S.
Food and Drug Administration (FDA) to market its new SRT-100+,
which adds several innovative features to Sensus' existing SRT-100
product for non-melanoma skin cancer and keloid treatment.
"Keloids not only have a high recurrence rate, but they also
significantly affect a person's confidence and quality of life,"
said Dr. Kenrick Spence, medical
director at Hillcrest Plastic Surgery and board-certified plastic
surgeon. "As such, our team is constantly looking for better ways
to treat patients who are afflicted with keloids in the most
non-invasive, painless way possible. Once we heard about the
SRT-100+ it became a must-have for our practice given its
best-in-class live lesion and patient monitoring systems,
integration with electronic medical records and myriad other new
features to improve outcomes. We look forward to treating patients
with the SRT-100+ and providing an important option for the
treatment and prevention of keloids."
The SRT-100+ offers all the same features as the SRT-100, with
the addition of:
- An expanded energy range for customized, more precise
treatment
- Remote diagnostics, including operation tracking
- New X-ray tube with extended functionality and performance
- Advanced console and enhanced system mobility to optimize
clinical practice
"Sensus is committed to constantly innovating and creating
solutions that are truly life-changing for people all over the
world, and we have listened closely to both doctor and patient
feedback to create the sophisticated SRT-100+ to ensure patient
safety and comfort," added Joe
Sardano, Sensus Healthcare CEO. "Keloids are very common and
can develop in any place where trauma occurs, especially after
surgery. Both doctors and patients need an effective solution to
treat keloids and keep them away once and for all. Dr. Spence is
the kind of physician customer we value, with his dedication to
providing best-in-class options for his patients with keloids and
other scars."
About Sensus Healthcare
Sensus Healthcare, Inc. is a
medical device company that is committed to providing non-invasive
and cost-effective treatment for non-melanoma skin cancers and
keloids. Sensus uses a proprietary low-energy X-ray technology
known as superficial radiation therapy (SRT), which is a result of
over a decade of dedicated research and development. Sensus has
successfully incorporated SRT into its portfolio of treatment
devices, the SRT-100™, SRT-100+ and SRT-100 Vision™. To date, SRT
technology has been used to effectively and safely treat
oncological and non-oncological skin conditions in thousands of
patients. Sensus also offers Sensus Laser Systems, three
next-generation devices that showcase the latest in technology and
function for the aesthetic dermatology market.
For more information,
visit https://www.sensushealthcare.com.
Forward-Looking Statements
This press release includes
statements that are, or may be deemed, ''forward-looking
statements.'' In some cases, these forward-looking statements can
be identified by the use of forward-looking terminology, including
the terms "believes," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should,"
"approximately," "potential" or, in each case, their negative or
other variations thereon or comparable terminology, although not
all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events, competitive dynamics,
and healthcare, regulatory and scientific developments and depend
on the economic circumstances that may or may not occur in the
future or may occur on longer or shorter timelines than
anticipated. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this press release,
we caution you that forward-looking statements are not guarantees
of future performance and that our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of,
among other factors: our ability to achieve and sustain
profitability; market acceptance of our product lines; our ability
to successfully commercialize our products; our ability to compete
effectively in selling our products and services, including
responding to technological change and cost containment efforts of
our customers; our need and ability to obtain additional financing
in the future, as well as complying with the restrictions our
existing revolving credit facility imposes; our ability to expand,
manage and maintain our direct sales and marketing organizations;
our actual financial results may vary significantly from forecasts
and from period to period; our ability to successfully develop new
products, improve or enhance existing products or acquire
complementary products, technologies, services or businesses; our
ability to obtain and maintain intellectual property of sufficient
scope to adequately protect our products, and our ability to avoid
infringing or otherwise violating the intellectual property rights
of third parties; market risks regarding consolidation in the
healthcare industry; the willingness of healthcare providers to
purchase our products if coverage, reimbursement and pricing from
third party payors for procedures using our products declines; the
level and availability of government and third party payor
reimbursement for clinical procedures using our products; our
ability to effectively manage our anticipated growth, including
hiring and retaining qualified personnel; the regulatory
requirements applicable to us and our competitors; our ability to
manufacture our products to meet demand; our reliance on third
party manufacturers and sole- or single-source suppliers; our
ability to reduce the per unit manufacturing costs; our ability to
efficiently manage our manufacturing processes; the regulatory and
legal risks, and certain operating risks, that our international
operations subject us to; off label use of our products; the fact
that product quality issues or product defects may harm our
business; the accuracy of our financial statements and accounting
estimates, including allowances for accounts receivable and
inventory obsolescence; any product liability claims; limited
trading in our shares and the concentration of ownership of our
shares; cyberattacks and other data breaches and the adverse effect
on our reputation; new legislation, administrative rules, or
executive orders, including those that impact taxes and
international trade regulation; the provisions in our certificate
of incorporation, bylaws, or Delaware law that discourage takeovers or that
limit certain disputes to be brought exclusively in the
Delaware Court of Chancery;
concentration of our customers in the U.S. and China, including the concentration of sales to
one particular customer in the U.S.; and other risks described from
time to time in Sensus Healthcare's filings with the Securities and
Exchange Commission, including the Company's Annual Report on Form
10-K.
In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in
which we operate are consistent with the forward-looking statements
contained in this press release, they may not be predictive of
results or developments in future periods. Any forward-looking
statements that we make in this press release speak only as of the
date of such statement, and we undertake no obligation to update
such statements to reflect events or circumstances after the date
of this press release. You should read carefully our "Cautionary
Note Regarding Forward-Looking Information" and the factors
described in the "Risk Factors" section of our periodic reports
filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Media Contacts:
Caitlin
Kasunich / McKenna Miller
KCSA Strategic Communications
212-896-1241 / 347-487-6197
ckasunich@kcsa.com / mmiller@kcsa.com
Investor Contact:
Kim Sutton
Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sensus-healthcare-installs-first-groundbreaking-srt-100-superficial-radiation-therapy-system-for-treating-keloid-scars-300757440.html
SOURCE Sensus Healthcare, Inc.